Home › NDC Lookup › RxCUI directory › RxCUI 1191264

Fluocinolone acetonide 0.1 MG/ML / hydroquinone 40 MG/ML / tretinoin 0.5 MG/ML Topical Cre... — RxCUI 1191264

RxNorm drug concept · Semantic branded drug
RxCUI 1191264 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1191264
Official nameFluocinolone acetonide 0.1 MG/ML / hydroquinone 40 MG/ML / tretinoin 0.5 MG/ML Topical Cream [Tri-Luma]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asTri-Luma (fluocinolone acetonide 0.01 % / hydroquinone 4 % / tretinoin 0.05 % ) Topical Cream; Tri-Luma 0.01 % / 4 % / 0.05 % Topical Cream
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)152 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tretinoin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It depends on the form. Creams, gels and lotions treat acne, and Renova eases fine facial wrinkles. The capsules treat a blood cancer called acute promyelocytic leukemia.
  • Wash the area, pat dry, and apply a thin layer once daily, usually in the evening. Keep it away from your eyes, mouth, nose creases and mucous membranes. More does not work faster...
  • Mild warmth or stinging, redness and peeling are common. If it becomes severe, call your prescriber, who may have you use less or pause. Acne can seem to flare early on, which is n...
  • What side effects should I expect on the skin?
📖 Read our full Tretinoin guide →

🕸️ Concept Web — How Fluocinolone acetonide 0.1 MG/ML / hydroquinone... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Fluocinolone acetonide 0.1 MG/ML / hydroquinone 40 MG/ML / tretinoin 0.5 MG/ML Topical Cream [Tri-Luma] RxCUI 1191264

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Fluocinolone 25126
    • Hydroquinone 5509
    • Tretinoin 10753
    • Fluocinolone / hydroquinone / tretinoin 465680
    • Fluocinolone acetonide 4461
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Tri-Luma 353031
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Fluocinolone / hydroquinone / tretinoin Topical Cream 378718
    • Fluocinolone acetonide / hydroquinone / tretinoin Topical Cream 2647926
    • Fluocinolone / hydroquinone / tretinoin Topical Product 1165638
    • Fluocinolone acetonide / hydroquinone / tretinoin Topical Product 2662348
    • Fluocinolone / hydroquinone / tretinoin Topical Cream [Tri-Luma] 362075
    • Fluocinolone acetonide / hydroquinone / tretinoin Topical Cream [Tri-Luma] 2657054
    • Tri-Luma Topical Product 1179714
    • Topical Cream 316982
    • +1 more in this family
  4. Clinical & branded drugs 5

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 19 of 20 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Fluocinolone acetonide 0.1 MG/ML / hydroquinone 40 MG/ML / tretinoin 0.5 MG/ML Topical Cream SCD · 1191262
  • Fluocinolone acetonide 0.1 MG/ML SCDC · 1191261
  • Hydroquinone 40 MG/ML SCDC · 329851
  • Tretinoin 0.5 MG/ML SCDC · 328693
  • Fluocinolone / hydroquinone / tretinoin Topical Cream SCDF · 378718
  • Fluocinolone acetonide / hydroquinone / tretinoin Topical Cream SCDFP · 2647926
  • Fluocinolone / hydroquinone / tretinoin Topical Product SCDG · 1165638
  • Fluocinolone acetonide / hydroquinone / tretinoin Topical Product SCDGP · 2662348

Brand-Name Concepts

  • Fluocinolone acetonide 0.1 MG/ML / hydroquinone 40 MG/ML / tretinoin 0.5 MG/ML [Tri-Luma] SBDC · 1191263
  • Fluocinolone / hydroquinone / tretinoin Topical Cream [Tri-Luma] SBDF · 362075
  • Fluocinolone acetonide / hydroquinone / tretinoin Topical Cream [Tri-Luma] SBDFP · 2657054
  • Tri-Luma Topical Product SBDG · 1179714
  • Tri-Luma BN · 353031

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 1191264 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00299-5950-02 1 TUBE in 1 BLISTER PACK (0299-5950-02) / 3 g in 1 TUBE TRI-LUMA Galderma Laboratories, L.P. 2012-04-01
00299-5950-30 1 TUBE in 1 CARTON (0299-5950-30) / 30 g in 1 TUBE TRI-LUMA Galderma Laboratories, L.P. 2007-01-18
Observed labelers: Galderma Laboratories, L.P. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per gm · median
$7.8233
Range $7.8233–$7.8233 · middle 50% $7.8233–$7.8233 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.